Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03517137
Title Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab

Age Groups: senior | adult
Covered Countries ESP | BEL


No variant requirements are available.